Journal of Affective Disorders
Volume 105, Issue 1 , Pages 15-23, January 2008

The selegiline transdermal system in major depressive disorder: A systematic review of safety and tolerability☆

  • Donald S. Robinson

      Affiliations

    • Worldwide Drug Development, 102 East Avenue, Burlington, VT 05401, United States
    • Corresponding Author InformationCorresponding author. Tel.: +1 802 658 2961.
    • ,
  • Jay D. Amsterdam

      Affiliations

    • Depression Research Unit, Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA, United States

Received 19 December 2006; received in revised form 4 April 2007; accepted 24 April 2007.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

☆ Role of funding source: Data in this report were derived from research studies sponsored and funded by Somerset Pharmaceuticals, Inc. (Tampa, FL). Preparation of the report was partially funded by Bristol-Myers Squibb (Princeton, NJ) and The Jack Warsaw Endowment for Research in Biological Psychiatry of the University of Pennsylvania Medical Center (Dr. Amsterdam). Conflict of interest: Dr. Robinson has served as consultant to Bristol-Myers Squibb, Somerset Pharmaceuticals, Epix, Genaissance, Medicinova, and Ono Pharmaceuticals. Dr. Amsterdam has served as scientific consultant to Bristol-Myers Squibb and Somerset Pharmaceuticals. Contributors: Dr. Robinson analyzed and reviewed safety data in the selegiline transdermal system NDA submitted to the Food and Drug Administration by Somerset Pharmaceuticals, Inc. Dr. Robinson wrote the first draft of the manuscript. Both authors were involved with literature review, preparation, and final approval of the report.

PII: S0165-0327(07)00148-6

doi:10.1016/j.jad.2007.04.024

Journal of Affective Disorders
Volume 105, Issue 1 , Pages 15-23, January 2008

Article Tools